BioScience Health Innovations Reports Net Income of $426,798 and Revenue Growth to $1.23M

BioScience Health Innovations, Inc. (formerly NowTransit Inc.) reported significant financial growth in its latest quarterly filing, revealing a net income of $426,798 for the three months ending March 31, 2025, compared to a net loss of $53,381 during the same period in 2024. The company generated revenues of $1,227,070, marking a substantial increase from $277,601 in the previous year. This growth is attributed to enhanced sales and marketing efforts, which have successfully expanded the company's customer base and product offerings.

The company's total assets rose to $1,394,959 as of March 31, 2025, up from $873,788 at the end of 2024. This increase was driven by a significant rise in inventory, which grew to $215,696 from $58,319, and cash and cash equivalents, which increased to $1,028,342 from $662,517. However, current liabilities also saw a notable rise, climbing to $132,921 from $38,548, primarily due to increased accounts payable and deferred revenue, which reflects the company's growing operational scale.

Strategically, BioScience Health Innovations has undergone a corporate name change and has focused on expanding its product line, which includes various health and wellness products aimed at addressing mental health and general wellness. The company has also filed several patent applications for its innovative products, including a proprietary oral delivery system for GLP-1 receptor agonists, which positions it to capitalize on the growing demand for non-invasive health solutions. The management team is optimistic about the potential for these products in the market, particularly in areas such as mitochondrial health and cognitive support.

Operationally, the company has reported positive cash flows from operating activities, amounting to $328,309 for the first quarter of 2025, a significant turnaround from the cash outflow of $48,040 in the same quarter of 2024. The company has also indicated plans to raise additional capital through a private placement to support its growth initiatives. Despite the positive financial performance, management has acknowledged ongoing concerns regarding liquidity and the need for further funding to ensure long-term operational sustainability.

Looking ahead, BioScience Health Innovations aims to leverage its recent growth and product innovations to capture a larger share of the health and wellness market. The company is targeting a year-over-year revenue growth of 35-50% through 2030, driven by its unique product offerings and strategic partnerships. However, management has cautioned that the ability to continue as a going concern will depend on successfully implementing its business plan and securing additional funding.